| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 4/9/2024, p1603-1603, 1p |
| Abstrakt: |
A recent report discusses research on melanoma treatment using a combination of nivolumab and ipilimumab therapy. The study analyzed data from patients with stage IV melanoma who were treated at two regional oncology centers in Romania from 2019 to 2022. The study found that patients with three or more metastases had higher lactate dehydrogenase (LDH) levels compared to those with only one metastatic site. The overall survival (OS) and progression-free survival (PFS) rates were 346 days and 211 days, respectively. Adverse events were experienced by 45.3% of patients, but the results showed improvement compared to previous chemotherapy regimens. The study provides real-world insights into the effectiveness and safety of combination therapy with anti-PD-1 and anti-CTLA-4 antibodies for melanoma treatment. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
